A novel, nontoxic iron chelator, super-polyphenol, effectively induces apoptosis in human cancer cell lines

Toshiaki Ohara, Yasuko Tomono, Xing Boyi, Sun Yingfu, Kazuhiro Omori, Akihiro Matsukawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Iron chelation therapy is the main treatment for iron overload disease. Iron chelators were recently reported to be useful for cancer therapy; however, they cause side effects that make them difficult to use in some cancer patients. Thus, a novel oral iron chelator, super-polyphenol (SP), was developed for cancer therapy to decrease the side effects. SP is either water soluble or insoluble, and has different isoforms according to the number of side chains. Of these isoforms, water-soluble SP6 and SP10 appear to be the best candidates, as they have the strongest chelating abilities. In this study, we focused on the usefulness and safety of SP6 and SP10 as anti-cancer drugs, and examined their anti-cancer effects and toxicity. The results showed that SP6 and SP10 inhibited cancer cell proliferation by inducing apoptosis in HCT116, HSC-2, A549, and MCF-7 cancer cells. SP10 also inhibited tumor growth in an HCT116 xenograft model. SP6 and SP10 had no acute toxicities. An intravenous injection test revealed that SP6 and SP10 had better safety profiles than the iron chelator deferoxamine. In conclusion, SP is a novel oral iron chelator with anti-cancer effects and few adverse side effects. This is the first report of SP in the literature.

Original languageEnglish
Pages (from-to)32751-32760
Number of pages10
JournalOncotarget
Volume9
Issue number67
DOIs
Publication statusPublished - Aug 28 2018

Fingerprint

Polyphenols
Chelating Agents
Iron
Apoptosis
Cell Line
Neoplasms
Protein Isoforms
Chelation Therapy
Safety
Deferoxamine
Iron Overload
Water
MCF-7 Cells
Heterografts
Intravenous Injections
Therapeutics
Cell Proliferation
Growth

Keywords

  • Apoptosis
  • Chelation
  • Chelator
  • Iron
  • Toxicity

ASJC Scopus subject areas

  • Oncology

Cite this

A novel, nontoxic iron chelator, super-polyphenol, effectively induces apoptosis in human cancer cell lines. / Ohara, Toshiaki; Tomono, Yasuko; Boyi, Xing; Yingfu, Sun; Omori, Kazuhiro; Matsukawa, Akihiro.

In: Oncotarget, Vol. 9, No. 67, 28.08.2018, p. 32751-32760.

Research output: Contribution to journalArticle

@article{ea96143d58e2418cbdea176d2ac54179,
title = "A novel, nontoxic iron chelator, super-polyphenol, effectively induces apoptosis in human cancer cell lines",
abstract = "Iron chelation therapy is the main treatment for iron overload disease. Iron chelators were recently reported to be useful for cancer therapy; however, they cause side effects that make them difficult to use in some cancer patients. Thus, a novel oral iron chelator, super-polyphenol (SP), was developed for cancer therapy to decrease the side effects. SP is either water soluble or insoluble, and has different isoforms according to the number of side chains. Of these isoforms, water-soluble SP6 and SP10 appear to be the best candidates, as they have the strongest chelating abilities. In this study, we focused on the usefulness and safety of SP6 and SP10 as anti-cancer drugs, and examined their anti-cancer effects and toxicity. The results showed that SP6 and SP10 inhibited cancer cell proliferation by inducing apoptosis in HCT116, HSC-2, A549, and MCF-7 cancer cells. SP10 also inhibited tumor growth in an HCT116 xenograft model. SP6 and SP10 had no acute toxicities. An intravenous injection test revealed that SP6 and SP10 had better safety profiles than the iron chelator deferoxamine. In conclusion, SP is a novel oral iron chelator with anti-cancer effects and few adverse side effects. This is the first report of SP in the literature.",
keywords = "Apoptosis, Chelation, Chelator, Iron, Toxicity",
author = "Toshiaki Ohara and Yasuko Tomono and Xing Boyi and Sun Yingfu and Kazuhiro Omori and Akihiro Matsukawa",
year = "2018",
month = "8",
day = "28",
doi = "10.18632/oncotarget.25973",
language = "English",
volume = "9",
pages = "32751--32760",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "67",

}

TY - JOUR

T1 - A novel, nontoxic iron chelator, super-polyphenol, effectively induces apoptosis in human cancer cell lines

AU - Ohara, Toshiaki

AU - Tomono, Yasuko

AU - Boyi, Xing

AU - Yingfu, Sun

AU - Omori, Kazuhiro

AU - Matsukawa, Akihiro

PY - 2018/8/28

Y1 - 2018/8/28

N2 - Iron chelation therapy is the main treatment for iron overload disease. Iron chelators were recently reported to be useful for cancer therapy; however, they cause side effects that make them difficult to use in some cancer patients. Thus, a novel oral iron chelator, super-polyphenol (SP), was developed for cancer therapy to decrease the side effects. SP is either water soluble or insoluble, and has different isoforms according to the number of side chains. Of these isoforms, water-soluble SP6 and SP10 appear to be the best candidates, as they have the strongest chelating abilities. In this study, we focused on the usefulness and safety of SP6 and SP10 as anti-cancer drugs, and examined their anti-cancer effects and toxicity. The results showed that SP6 and SP10 inhibited cancer cell proliferation by inducing apoptosis in HCT116, HSC-2, A549, and MCF-7 cancer cells. SP10 also inhibited tumor growth in an HCT116 xenograft model. SP6 and SP10 had no acute toxicities. An intravenous injection test revealed that SP6 and SP10 had better safety profiles than the iron chelator deferoxamine. In conclusion, SP is a novel oral iron chelator with anti-cancer effects and few adverse side effects. This is the first report of SP in the literature.

AB - Iron chelation therapy is the main treatment for iron overload disease. Iron chelators were recently reported to be useful for cancer therapy; however, they cause side effects that make them difficult to use in some cancer patients. Thus, a novel oral iron chelator, super-polyphenol (SP), was developed for cancer therapy to decrease the side effects. SP is either water soluble or insoluble, and has different isoforms according to the number of side chains. Of these isoforms, water-soluble SP6 and SP10 appear to be the best candidates, as they have the strongest chelating abilities. In this study, we focused on the usefulness and safety of SP6 and SP10 as anti-cancer drugs, and examined their anti-cancer effects and toxicity. The results showed that SP6 and SP10 inhibited cancer cell proliferation by inducing apoptosis in HCT116, HSC-2, A549, and MCF-7 cancer cells. SP10 also inhibited tumor growth in an HCT116 xenograft model. SP6 and SP10 had no acute toxicities. An intravenous injection test revealed that SP6 and SP10 had better safety profiles than the iron chelator deferoxamine. In conclusion, SP is a novel oral iron chelator with anti-cancer effects and few adverse side effects. This is the first report of SP in the literature.

KW - Apoptosis

KW - Chelation

KW - Chelator

KW - Iron

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85052501265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052501265&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.25973

DO - 10.18632/oncotarget.25973

M3 - Article

AN - SCOPUS:85052501265

VL - 9

SP - 32751

EP - 32760

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 67

ER -